Drug Repurposing of Bromodomain Inhibitors as Potential Novel Therapeutic Leads for Lymphatic Filariasis Guided by Multispecies Transcriptomics

The current treatment regimen for lymphatic filariasis is mostly microfilaricidal. In an effort to identify new drug candidates for lymphatic filariasis, we conducted a three-way transcriptomics/systems biology study of one of the causative agents of lymphatic filariasis, Brugia malayi, its Wolbachi...

Full description

Bibliographic Details
Main Authors: Matthew Chung, Laura E. Teigen, Silvia Libro, Robin E. Bromley, Dustin Olley, Nikhil Kumar, Lisa Sadzewicz, Luke J. Tallon, Anup Mahurkar, Jeremy M. Foster, Michelle L. Michalski, Julie C. Dunning Hotopp
Format: Article
Language:English
Published: American Society for Microbiology 2019-12-01
Series:mSystems
Subjects:
Online Access:https://doi.org/10.1128/mSystems.00596-19
id doaj-e4e16df044534a02989c09ec336d7922
record_format Article
spelling doaj-e4e16df044534a02989c09ec336d79222020-11-25T02:26:26ZengAmerican Society for MicrobiologymSystems2379-50772019-12-0146e00596-1910.1128/mSystems.00596-19Drug Repurposing of Bromodomain Inhibitors as Potential Novel Therapeutic Leads for Lymphatic Filariasis Guided by Multispecies TranscriptomicsMatthew ChungLaura E. TeigenSilvia LibroRobin E. BromleyDustin OlleyNikhil KumarLisa SadzewiczLuke J. TallonAnup MahurkarJeremy M. FosterMichelle L. MichalskiJulie C. Dunning HotoppThe current treatment regimen for lymphatic filariasis is mostly microfilaricidal. In an effort to identify new drug candidates for lymphatic filariasis, we conducted a three-way transcriptomics/systems biology study of one of the causative agents of lymphatic filariasis, Brugia malayi, its Wolbachia endosymbiont wBm, and its vector host Aedes aegypti at 16 distinct B. malayi life stages. B. malayi upregulates the expression of bromodomain-containing proteins in the adult female, embryo, and microfilaria stages. In vitro, we find that the existing cancer therapeutic JQ1(+), which is a bromodomain and extraterminal protein inhibitor, has adulticidal activity in B. malayi.To better understand the transcriptomic interplay of organisms associated with lymphatic filariasis, we conducted multispecies transcriptome sequencing (RNA-Seq) on the filarial nematode Brugia malayi, its Wolbachia endosymbiont wBm, and its laboratory vector Aedes aegypti across the entire B. malayi life cycle. In wBm, transcription of the noncoding 6S RNA suggests that it may be a regulator of bacterial cell growth, as its transcript levels correlate with bacterial replication rates. For A. aegypti, the transcriptional response reflects the stress that B. malayi infection exerts on the mosquito with indicators of increased energy demand. In B. malayi, expression modules associated with adult female samples consistently contained an overrepresentation of genes involved in chromatin remodeling, such as the bromodomain-containing proteins. All bromodomain-containing proteins encoded by B. malayi were observed to be upregulated in the adult female, embryo, and microfilaria life stages, including 2 members of the bromodomain and extraterminal (BET) protein family. The BET inhibitor JQ1(+), originally developed as a cancer therapeutic, caused lethality of adult worms in vitro, suggesting that it may be a potential therapeutic that can be repurposed for treating lymphatic filariasis.https://doi.org/10.1128/mSystems.00596-19lymphatic filariasisfilarial nematodesnematodesbrugia malayiwolbachiaaedes aegyptimosquitotranscriptomicsrna-seqmultispecies rna-seqbromodomainbromodomain inhibitor6s rnabrugiadrug repurposingneglected tropical diseasesymbiosis
collection DOAJ
language English
format Article
sources DOAJ
author Matthew Chung
Laura E. Teigen
Silvia Libro
Robin E. Bromley
Dustin Olley
Nikhil Kumar
Lisa Sadzewicz
Luke J. Tallon
Anup Mahurkar
Jeremy M. Foster
Michelle L. Michalski
Julie C. Dunning Hotopp
spellingShingle Matthew Chung
Laura E. Teigen
Silvia Libro
Robin E. Bromley
Dustin Olley
Nikhil Kumar
Lisa Sadzewicz
Luke J. Tallon
Anup Mahurkar
Jeremy M. Foster
Michelle L. Michalski
Julie C. Dunning Hotopp
Drug Repurposing of Bromodomain Inhibitors as Potential Novel Therapeutic Leads for Lymphatic Filariasis Guided by Multispecies Transcriptomics
mSystems
lymphatic filariasis
filarial nematodes
nematodes
brugia malayi
wolbachia
aedes aegypti
mosquito
transcriptomics
rna-seq
multispecies rna-seq
bromodomain
bromodomain inhibitor
6s rna
brugia
drug repurposing
neglected tropical disease
symbiosis
author_facet Matthew Chung
Laura E. Teigen
Silvia Libro
Robin E. Bromley
Dustin Olley
Nikhil Kumar
Lisa Sadzewicz
Luke J. Tallon
Anup Mahurkar
Jeremy M. Foster
Michelle L. Michalski
Julie C. Dunning Hotopp
author_sort Matthew Chung
title Drug Repurposing of Bromodomain Inhibitors as Potential Novel Therapeutic Leads for Lymphatic Filariasis Guided by Multispecies Transcriptomics
title_short Drug Repurposing of Bromodomain Inhibitors as Potential Novel Therapeutic Leads for Lymphatic Filariasis Guided by Multispecies Transcriptomics
title_full Drug Repurposing of Bromodomain Inhibitors as Potential Novel Therapeutic Leads for Lymphatic Filariasis Guided by Multispecies Transcriptomics
title_fullStr Drug Repurposing of Bromodomain Inhibitors as Potential Novel Therapeutic Leads for Lymphatic Filariasis Guided by Multispecies Transcriptomics
title_full_unstemmed Drug Repurposing of Bromodomain Inhibitors as Potential Novel Therapeutic Leads for Lymphatic Filariasis Guided by Multispecies Transcriptomics
title_sort drug repurposing of bromodomain inhibitors as potential novel therapeutic leads for lymphatic filariasis guided by multispecies transcriptomics
publisher American Society for Microbiology
series mSystems
issn 2379-5077
publishDate 2019-12-01
description The current treatment regimen for lymphatic filariasis is mostly microfilaricidal. In an effort to identify new drug candidates for lymphatic filariasis, we conducted a three-way transcriptomics/systems biology study of one of the causative agents of lymphatic filariasis, Brugia malayi, its Wolbachia endosymbiont wBm, and its vector host Aedes aegypti at 16 distinct B. malayi life stages. B. malayi upregulates the expression of bromodomain-containing proteins in the adult female, embryo, and microfilaria stages. In vitro, we find that the existing cancer therapeutic JQ1(+), which is a bromodomain and extraterminal protein inhibitor, has adulticidal activity in B. malayi.To better understand the transcriptomic interplay of organisms associated with lymphatic filariasis, we conducted multispecies transcriptome sequencing (RNA-Seq) on the filarial nematode Brugia malayi, its Wolbachia endosymbiont wBm, and its laboratory vector Aedes aegypti across the entire B. malayi life cycle. In wBm, transcription of the noncoding 6S RNA suggests that it may be a regulator of bacterial cell growth, as its transcript levels correlate with bacterial replication rates. For A. aegypti, the transcriptional response reflects the stress that B. malayi infection exerts on the mosquito with indicators of increased energy demand. In B. malayi, expression modules associated with adult female samples consistently contained an overrepresentation of genes involved in chromatin remodeling, such as the bromodomain-containing proteins. All bromodomain-containing proteins encoded by B. malayi were observed to be upregulated in the adult female, embryo, and microfilaria life stages, including 2 members of the bromodomain and extraterminal (BET) protein family. The BET inhibitor JQ1(+), originally developed as a cancer therapeutic, caused lethality of adult worms in vitro, suggesting that it may be a potential therapeutic that can be repurposed for treating lymphatic filariasis.
topic lymphatic filariasis
filarial nematodes
nematodes
brugia malayi
wolbachia
aedes aegypti
mosquito
transcriptomics
rna-seq
multispecies rna-seq
bromodomain
bromodomain inhibitor
6s rna
brugia
drug repurposing
neglected tropical disease
symbiosis
url https://doi.org/10.1128/mSystems.00596-19
work_keys_str_mv AT matthewchung drugrepurposingofbromodomaininhibitorsaspotentialnoveltherapeuticleadsforlymphaticfilariasisguidedbymultispeciestranscriptomics
AT lauraeteigen drugrepurposingofbromodomaininhibitorsaspotentialnoveltherapeuticleadsforlymphaticfilariasisguidedbymultispeciestranscriptomics
AT silvialibro drugrepurposingofbromodomaininhibitorsaspotentialnoveltherapeuticleadsforlymphaticfilariasisguidedbymultispeciestranscriptomics
AT robinebromley drugrepurposingofbromodomaininhibitorsaspotentialnoveltherapeuticleadsforlymphaticfilariasisguidedbymultispeciestranscriptomics
AT dustinolley drugrepurposingofbromodomaininhibitorsaspotentialnoveltherapeuticleadsforlymphaticfilariasisguidedbymultispeciestranscriptomics
AT nikhilkumar drugrepurposingofbromodomaininhibitorsaspotentialnoveltherapeuticleadsforlymphaticfilariasisguidedbymultispeciestranscriptomics
AT lisasadzewicz drugrepurposingofbromodomaininhibitorsaspotentialnoveltherapeuticleadsforlymphaticfilariasisguidedbymultispeciestranscriptomics
AT lukejtallon drugrepurposingofbromodomaininhibitorsaspotentialnoveltherapeuticleadsforlymphaticfilariasisguidedbymultispeciestranscriptomics
AT anupmahurkar drugrepurposingofbromodomaininhibitorsaspotentialnoveltherapeuticleadsforlymphaticfilariasisguidedbymultispeciestranscriptomics
AT jeremymfoster drugrepurposingofbromodomaininhibitorsaspotentialnoveltherapeuticleadsforlymphaticfilariasisguidedbymultispeciestranscriptomics
AT michellelmichalski drugrepurposingofbromodomaininhibitorsaspotentialnoveltherapeuticleadsforlymphaticfilariasisguidedbymultispeciestranscriptomics
AT juliecdunninghotopp drugrepurposingofbromodomaininhibitorsaspotentialnoveltherapeuticleadsforlymphaticfilariasisguidedbymultispeciestranscriptomics
_version_ 1715486102365667328